SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro DiagnosticsLiquid Biopsy

PUBLISHER: Meticulous Research | PRODUCT CODE: 2138417

Cover Image

PUBLISHER: Meticulous Research | PRODUCT CODE: 2138417

Liquid Biopsy Market by Products and Services, Biomarker/Analyte, Sample Type, Application, Cancer Type, End User, and Geography - Global Forecast to 2036

PUBLISHED:
PAGES: 306 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4175
PDF & Excel (Multi User License)
USD 5875
PDF & Excel (Global Site License)
USD 7875

Add to Cart

Description

Table of Contents

List of Tables

The global Liquid Biopsy Market was valued at USD 3,449.9 million in 2025. It is estimated to reach USD 4,340.0 million in 2026 and is projected to grow to USD 16,218.1 million by 2036, at a CAGR of 14.1% during the forecast period. In volume terms, the market is projected to reach 22,294.6 thousand tests by 2036. This report offers a detailed look at the market, covering key trends, technologies, regulations, pricing and reimbursement, test volumes, competitive activity, and future growth opportunities.

Liquid biopsy detects and analyzes tumor-derived material, such as circulating tumor DNA, circulating tumor cells, and extracellular vesicles, in blood and other body fluids. It is used to choose targeted therapies, monitor treatment response, detect molecular residual disease and recurrence after treatment, and screen for cancer. Plasma-based testing is now a routine part of oncology care, as more than thirty companion diagnostic approvals reference liquid biopsy and tissue samples are often insufficient for molecular profiling.

Commercial activity is growing quickly across the category. Guardant Health reported revenue of USD 982.0 million in 2025, up 33%, Natera's oncology test volumes grew from about 167,700 to 258,900 in a year, and Caris Life Sciences completed its initial public offering in June 2025. The market is also consolidating, with Abbott completing its USD 21 billion acquisition of Exact Sciences in March 2026 and Tempus AI agreeing in July 2026 to acquire Personalis for about USD 1.5 billion. In February 2026, U.S. legislation created a Medicare benefit category for multi-cancer early detection tests, with coverage possible from 2028.

The report examines market drivers and restraints, key trends, technologies such as next-generation sequencing, digital PCR, methylation and fragmentomics, and cell capture, the value chain, regulations across major regions, pricing, test volumes and reimbursement, and competitive strategies. It explains why test volumes are growing faster than revenue as lower-priced monitoring and screening tests expand. It also provides market forecasts, segment-level insights, and regional analysis across 5 regions and 24 countries and sub-regions to support business, investment, and product decisions.

Market Dynamics

Rising cancer incidence is a key driver of market growth. The World Health Organization records about 20 million new cancer cases in 2022 and expects about 35 million by 2050, and each patient may need several tests across diagnosis, progression, and post-treatment monitoring. The growing number of targeted therapies approved with companion diagnostics also creates a mandatory testing requirement for every eligible patient, and the U.S. oncology pipeline contains more than 1,600 medicines in development, many of which require biomarker testing.

Early-stage and low-shedding tumors release very little DNA into the blood, so a negative result often requires follow-up tissue testing, which limits how far liquid biopsy can replace tissue biopsy. Reimbursement is also incomplete outside therapy selection, with screening largely unreimbursed and coverage in Europe, Asia, Latin America, and the Middle East narrower than in the U.S. In addition, the lack of standardized collection, processing, and reporting protocols makes results harder to compare across laboratories and over time.

Multi-cancer early detection is the largest expansion opportunity, as it targets the healthy adult population rather than only diagnosed patients, and new Medicare legislation and pending FDA filings are moving it closer to the market. Pharmaceutical companies are also becoming an important customer group, using ctDNA-based endpoints in clinical trials and partnering on companion diagnostic development. Meanwhile, molecular residual disease testing is becoming standard of care in solid tumors, and multi-cancer screening is approaching key regulatory and coverage milestones.

Segment Analysis

The report analyzes the market by products and services, biomarker/analyte, sample type, application, cancer type, end user, and geography, helping stakeholders identify the most promising growth opportunities.

Based on products and services, the market is segmented into laboratory testing services, assays and kits, instruments, and software and data services. In 2026, laboratory testing services are expected to account for the largest share of the market, as leading companies perform tests in their own laboratories and sell results rather than distributing assays. Software and data services are expected to grow the fastest, as test interpretation becomes a separate service and real-world data businesses built on testing volumes expand.

Based on biomarker/analyte, the market is segmented into circulating tumor DNA, other cell-free DNA approaches, circulating tumor cells, extracellular vesicles, and other analytes. In 2026, circulating tumor DNA is expected to hold the largest share, as it is used in every FDA-approved liquid biopsy companion diagnostic and in leading MRD tests. Extracellular vesicles are expected to grow the fastest from a small base, supported by the richer biological information they carry and their suitability for non-blood samples.

Based on sample type, the market is segmented into blood (plasma/serum), urine, cerebrospinal fluid, saliva, and other sample types. In 2026, blood is expected to hold the largest share, as every commercially significant test analyzes plasma or serum. Urine is expected to grow the fastest, supported by easy self-collection and its relevance to urological cancers.

Based on application, the market is segmented into therapy selection and companion diagnostics; treatment monitoring, molecular residual disease and recurrence; cancer screening and early detection; and pharmaceutical research and clinical trial services. In 2026, therapy selection and companion diagnostics is expected to hold the largest share, as it is the most widely reimbursed application. Cancer screening and early detection is expected to grow the fastest, supported by the FDA approval and payer coverage of blood-based colorectal screening and the new Medicare benefit category for multi-cancer screening.

Based on cancer type, the market is segmented into lung, breast, colorectal, prostate, liver, pancreatic, and other cancer types. In 2026, lung cancer is expected to hold the largest share, given the many targetable mutations in non-small cell lung cancer and the frequent shortage of tissue for testing. Pancreatic cancer is expected to grow the fastest, driven by high clinical need and active early detection research.

Based on end user, the market is segmented into diagnostic and reference laboratories, hospitals and clinics, pharmaceutical and biotechnology companies, and academic and research institutes. In 2026, diagnostic and reference laboratories are expected to hold the largest share, as most testing is performed in centralized specialist laboratories. Pharmaceutical and biotechnology companies are expected to grow the fastest, driven by ctDNA endpoints in oncology trials and companion diagnostic co-development.

Regional Analysis

The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 24 countries and sub-regions. The regional analysis considers cancer burden, regulatory pathways, reimbursement and pricing, test volumes, the presence of testing providers and suppliers, and access to oncology care.

In 2026, North America is expected to account for the largest share of the global market, with the U.S. as the largest country market. The region combines the most flexible route to market, as CLIA-certified laboratories can offer validated tests without premarket review, with the most developed reimbursement system for molecular diagnostics. It is also home to most of the companies that define the market, including Guardant Health, Natera, Tempus AI, Caris Life Sciences, Foundation Medicine, and Exact Sciences.

Asia-Pacific is expected to grow the fastest during the forecast period, driven by the largest cancer burden of any region, rapidly expanding oncology infrastructure, and low current testing rates. China is the largest market in the region and India is expected to grow the fastest, while domestic providers such as AmoyDx and Burning Rock Biotech offer lower-cost testing. Europe has strong clinical adoption, but budgeted national funding and the In Vitro Diagnostic Regulation limit the value captured per test, with Germany as the largest market. Latin America and the Middle East & Africa are smaller markets, where growth depends on private insurance, out-of-pocket payment, and, in the Gulf states, precision medicine priorities.

Competitive Landscape

The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard, and market share analysis, together with profiles of leading companies including their financial performance, product portfolios, strategic developments, and SWOT analyses.

The liquid biopsy market changed more between late 2024 and mid-2026 than in the preceding five years. Competition now spans applications that were once separate, with many companies competing in both therapy selection and molecular residual disease testing, and companies compete mainly on clinical evidence and reimbursement coverage rather than price. Based on 2025 market share, Natera ranked first, driven by its Signatera MRD test, followed by Guardant Health and Roche. Acquisitions and corporate transactions were the most common strategy, including Abbott's acquisition of Exact Sciences and Tempus AI's planned acquisition of Personalis, followed by product development and partnerships.

The competitive benchmarking compares companies on the applications they serve, their regulatory and reimbursement position, and their commercial model, distinguishing testing providers that operate central laboratories from product suppliers that sell assays, instruments, and consumables. Companies compete on clinical evidence, test sensitivity, coverage decisions, breadth across applications, and access to pharmaceutical partners.

Key companies profiled in the report include Guardant Health, Inc. (U.S.), Roche Diagnostics, including Foundation Medicine (Switzerland), Natera, Inc. (U.S.), Abbott Laboratories, including Exact Sciences Corporation (U.S.), Tempus AI, Inc. (U.S.), Caris Life Sciences, Inc. (U.S.), Personalis, Inc. (U.S.), Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Bio-Rad Laboratories, Inc. (U.S.), NeoGenomics, Inc. (U.S.), Myriad Genetics, Inc. (U.S.), Sysmex Corporation (Japan), Menarini Silicon Biosystems (Italy), BillionToOne, Inc. (U.S.), Burning Rock Biotech Limited (China), and Amoy Diagnostics Co., Ltd. (China).

How This Report Helps

  • Provides reliable market size estimates and long-term forecasts for the global liquid biopsy market, along with test volume projections.
  • Explains how cancer incidence, companion diagnostic approvals, clinical evidence, reimbursement, and regulations affect market growth.
  • Identifies high-growth opportunities across products and services, biomarker/analyte, sample type, application, cancer type, end user, and region.
  • Analyzes technologies, regulations, pricing, test volumes, reimbursement, and the value chain shaping the market.
  • Benchmarks leading companies based on their applications, regulatory and coverage position, commercial models, and market share.
  • Supports product development, partnership evaluation, investment planning, market entry, and business expansion decisions.
  • Delivers practical market insights for diagnostics companies, testing laboratories, instrument and assay suppliers, pharmaceutical companies, healthcare providers, payers, and investors.

Key Questions Answered

  • How big is the global liquid biopsy market today, and how will it grow through 2036?
  • What clinical, regulatory, and reimbursement factors are driving market growth?
  • What are the main drivers, restraints, opportunities, and challenges shaping the industry?
  • Which products and services, biomarker, sample type, application, cancer type, end user, and regional segments will grow the fastest?
  • How are molecular residual disease testing and blood-based cancer screening changing the market?
  • Why are test volumes growing faster than revenue, and how are prices changing by application and region?
  • Which regions and countries offer the most attractive business opportunities?
  • Who are the leading companies in the market, and what strategies are they following?
  • What recent acquisitions, approvals, coverage decisions, and partnerships are shaping the competitive landscape?
Show more

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Scope
    • 1.2.1. Inclusion and Exclusion Criteria
  • 1.3. Market Ecosystem
  • 1.4. Currency and Limitations
    • 1.4.1. Currency
    • 1.4.2. Limitations
  • 1.5. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Process of Data Collection and Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
  • 2.3. Market Sizing and Forecasting
    • 2.3.1. Market Size Estimation Approach
      • 2.3.1.1. Bottom-Up Approach
      • 2.3.1.2. Top-Down Approach
    • 2.3.2. Growth Forecast Approach
    • 2.3.3. Market Share Analysis
  • 2.4. Data Triangulation
  • 2.5. Assumptions for the Study

3. Executive Summary

4. Market Insights

  • 4.1. Overview
  • 4.2. Factors Affecting Market Growth
    • 4.2.1. Rising Global Cancer Incidence Sustaining Demand for Molecular Testing
    • 4.2.2. Expanding Companion Diagnostic Approvals Creating Mandatory Testing Requirements
    • 4.2.3. Clinical Evidence Supporting ctDNA-Guided Treatment Decisions
    • 4.2.4. Reimbursement Expansion for Molecular Residual Disease Testing
    • 4.2.5. Limited Sensitivity in Early-Stage and Low-Shedding Tumors Restraining Adoption
    • 4.2.6. Incomplete Reimbursement Outside Therapy Selection Constraining Market Expansion
    • 4.2.7. Multi-Cancer Early Detection Presenting the Largest Expansion Opportunity
    • 4.2.8. Growth of Pharmaceutical Partnerships and ctDNA-Based Trial Endpoints
    • 4.2.9. Standardization of Testing Protocols Remaining a Challenge for Market Stakeholders
  • 4.3. Key Trends
    • 4.3.1. Minimal Residual Disease Detection Becoming Standard of Care in Solid Tumors
    • 4.3.2. Multi-Cancer Screening Approaching Regulatory and Coverage Milestones
    • 4.3.3. Consolidation Reshaping the Competitive Structure
    • 4.3.4. Integration of Artificial Intelligence into Result Interpretation
  • 4.4. Technology Landscape
    • 4.4.1. Next-Generation Sequencing
    • 4.4.2. Polymerase Chain Reaction and Digital PCR
    • 4.4.3. Methylation and Fragmentomics
    • 4.4.4. Cell Capture and Imaging Technologies
  • 4.5. Value Chain Analysis
  • 4.6. Regulatory Analysis
    • 4.6.1. U.S.
    • 4.6.2. Canada
    • 4.6.3. Europe
    • 4.6.4. China
    • 4.6.5. Japan
    • 4.6.6. India
    • 4.6.7. Latin America
    • 4.6.8. Middle East & Africa
  • 4.7. Pricing and Test Volume Analysis
    • 4.7.1. Price Levels by Clinical Application
    • 4.7.2. Realized Price by Region and Country
    • 4.7.3. Test Volume by Region and Country
    • 4.7.4. Reimbursement Landscape
  • 4.8. Porter's Five Forces Analysis
    • 4.8.1. Bargaining Power of Buyers: High
    • 4.8.2. Bargaining Power of Suppliers: Medium
    • 4.8.3. Threat of Substitutes: Medium to High
    • 4.8.4. Threat of New Entrants: Low to Medium
    • 4.8.5. Degree of Competition: High
  • 4.9. PESTEL Analysis

5. Liquid Biopsy Market Assessment-by Products and Services

  • 5.1. Overview
  • 5.2. Laboratory Testing Services
  • 5.3. Assays and Kits
  • 5.4. Instruments
  • 5.5. Software and Data Services

6. Liquid Biopsy Market Assessment-by Biomarker/Analyte

  • 6.1. Overview
  • 6.2. Circulating Tumor DNA
  • 6.3. Other Cell-Free DNA Approaches
  • 6.4. Circulating Tumor Cells
  • 6.5. Extracellular Vesicles
  • 6.6. Other Analytes

7. Liquid Biopsy Market Assessment-by Sample Type

  • 7.1. Overview
  • 7.2. Blood (Plasma/Serum)
  • 7.3. Urine
  • 7.4. Cerebrospinal Fluid
  • 7.5. Saliva
  • 7.6. Other Sample Types

8. Liquid Biopsy Market Assessment-by Application

  • 8.1. Overview
  • 8.2. Therapy Selection and Companion Diagnostics
  • 8.3. Treatment Monitoring, Molecular Residual Disease and Recurrence
  • 8.4. Cancer Screening and Early Detection
  • 8.5. Pharmaceutical Research and Clinical Trial Services

9. Liquid Biopsy Market Assessment-by Cancer Type

  • 9.1. Overview
  • 9.2. Lung Cancer
  • 9.3. Breast Cancer
  • 9.4. Colorectal Cancer
  • 9.5. Prostate Cancer
  • 9.6. Liver Cancer
  • 9.7. Pancreatic Cancer
  • 9.8. Other Cancer Types

10. Liquid Biopsy Market Assessment-by End User

  • 10.1. Overview
  • 10.2. Diagnostic and Reference Laboratories
  • 10.3. Hospitals and Clinics
  • 10.4. Pharmaceutical and Biotechnology Companies
  • 10.5. Academic and Research Institutes

11. Liquid Biopsy Market Assessment-by Geography

  • 11.1. Overview
  • 11.2. North America
    • 11.2.1. U.S.
    • 11.2.2. Canada
  • 11.3. Europe
    • 11.3.1. Germany
    • 11.3.2. U.K.
    • 11.3.3. France
    • 11.3.4. Italy
    • 11.3.5. Spain
    • 11.3.6. Netherlands
    • 11.3.7. Sweden
    • 11.3.8. Switzerland
    • 11.3.9. Rest of Europe
  • 11.4. Asia-Pacific
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. South Korea
    • 11.4.5. Australia
    • 11.4.6. Singapore
    • 11.4.7. Rest of Asia-Pacific
  • 11.5. Latin America
    • 11.5.1. Brazil
    • 11.5.2. Mexico
    • 11.5.3. Rest of Latin America
  • 11.6. Middle East & Africa
    • 11.6.1. U.A.E.
    • 11.6.2. Saudi Arabia
    • 11.6.3. South Africa
    • 11.6.4. Rest of Middle East & Africa

12. Competitive Landscape

  • 12.1. Overview
  • 12.2. Key Growth Strategies
  • 12.3. Competitive Benchmarking
  • 12.4. Competitive Dashboard
    • 12.4.1. Industry Leaders
    • 12.4.2. Market Differentiators
    • 12.4.3. Vanguards
    • 12.4.4. Emerging Companies
  • 12.5. Market Share Analysis

13. Company Profiles

  • 13.1. Guardant Health, Inc.
    • 13.1.1. Business Overview
    • 13.1.2. Financial Overview
    • 13.1.3. Product Portfolio
    • 13.1.4. Strategic Developments
    • 13.1.5. SWOT Analysis
  • 13.2. Roche Diagnostics (Including Foundation Medicine)
    • 13.2.1. Business Overview
    • 13.2.2. Financial Overview
    • 13.2.3. Product Portfolio
    • 13.2.4. Strategic Developments
    • 13.2.5. SWOT Analysis
  • 13.3. Natera, Inc.
    • 13.3.1. Business Overview
    • 13.3.2. Financial Overview
    • 13.3.3. Product Portfolio
    • 13.3.4. Strategic Developments
    • 13.3.5. SWOT Analysis
  • 13.4. Abbott Laboratories (Exact Sciences Corporation)
    • 13.4.1. Business Overview
    • 13.4.2. Financial Overview
    • 13.4.3. Product Portfolio
    • 13.4.4. Strategic Developments
    • 13.4.5. SWOT Analysis
  • 13.5. Tempus AI, Inc.
    • 13.5.1. Business Overview
    • 13.5.2. Financial Overview
    • 13.5.3. Product Portfolio
    • 13.5.4. Strategic Developments
    • 13.5.5. SWOT Analysis
  • 13.6. Caris Life Sciences, Inc.
    • 13.6.1. Business Overview
    • 13.6.2. Financial Overview
    • 13.6.3. Product Portfolio
    • 13.6.4. Strategic Developments
    • 13.6.5. SWOT Analysis
  • 13.7. Personalis, Inc.
    • 13.7.1. Business Overview
    • 13.7.2. Financial Overview
    • 13.7.3. Product Portfolio
    • 13.7.4. Strategic Developments
    • 13.7.5. SWOT Analysis
  • 13.8. Illumina, Inc.
    • 13.8.1. Business Overview
    • 13.8.2. Financial Overview
    • 13.8.3. Product Portfolio
    • 13.8.4. Strategic Developments
    • 13.8.5. SWOT Analysis
  • 13.9. Thermo Fisher Scientific Inc.
    • 13.9.1. Business Overview
    • 13.9.2. Financial Overview
    • 13.9.3. Product Portfolio
    • 13.9.4. Strategic Developments
    • 13.9.5. SWOT Analysis
  • 13.10. QIAGEN N.V.
    • 13.10.1. Business Overview
    • 13.10.2. Financial Overview
    • 13.10.3. Product Portfolio
    • 13.10.4. Strategic Developments
    • 13.10.5. SWOT Analysis
  • 13.11. Bio-Rad Laboratories, Inc.
    • 13.11.1. Business Overview
    • 13.11.2. Financial Overview
    • 13.11.3. Product Portfolio
    • 13.11.4. Strategic Developments
    • 13.11.5. SWOT Analysis
  • 13.12. NeoGenomics, Inc.
    • 13.12.1. Business Overview
    • 13.12.2. Financial Overview
    • 13.12.3. Product Portfolio
    • 13.12.4. Strategic Developments
    • 13.12.5. SWOT Analysis
  • 13.13. Myriad Genetics, Inc.
    • 13.13.1. Business Overview
    • 13.13.2. Financial Overview
    • 13.13.3. Product Portfolio
    • 13.13.4. Strategic Developments
    • 13.13.5. SWOT Analysis
  • 13.14. Sysmex Corporation
    • 13.14.1. Business Overview
    • 13.14.2. Financial Overview
    • 13.14.3. Product Portfolio
    • 13.14.4. Strategic Developments
    • 13.14.5. SWOT Analysis
  • 13.15. Menarini Silicon Biosystems
    • 13.15.1. Business Overview
    • 13.15.2. Financial Overview
    • 13.15.3. Product Portfolio
    • 13.15.4. Strategic Developments
    • 13.15.5. SWOT Analysis
  • 13.16. BillionToOne, Inc.
    • 13.16.1. Business Overview
    • 13.16.2. Financial Overview
    • 13.16.3. Product Portfolio
    • 13.16.4. Strategic Developments
    • 13.16.5. SWOT Analysis
  • 13.17. Burning Rock Biotech Limited
    • 13.17.1. Business Overview
    • 13.17.2. Financial Overview
    • 13.17.3. Product Portfolio
    • 13.17.4. Strategic Developments
    • 13.17.5. SWOT Analysis
  • 13.18. Amoy Diagnostics Co., Ltd. (AmoyDx)
    • 13.18.1. Business Overview
    • 13.18.2. Financial Overview
    • 13.18.3. Product Portfolio
    • 13.18.4. Strategic Developments
    • 13.18.5. SWOT Analysis

14. Appendix

  • 14.1. Available Customization
  • 14.2. Related Reports
Show more

LIST OF TABLES

List of Tables

  • Table 1. Test-Level Inclusion Assessment, by Leading Product (2026)
  • Table 2. Technology Landscape of the Liquid Biopsy Market
  • Table 3. Realized Price per Test, by Country/Region, 2024-2036 (USD)
  • Table 4. Test Volume, by Country/Region, 2024-2036 (Thousand Tests)
  • Table 5. Global Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 6. Global Liquid Biopsy Market for Laboratory Testing Services, by Country/Region, 2024-2036 (USD Million)
  • Table 7. Global Liquid Biopsy Assays and Kits Market, by Country/Region, 2024-2036 (USD Million)
  • Table 8. Global Liquid Biopsy Instruments Market, by Country/Region, 2024-2036 (USD Million)
  • Table 9. Global Liquid Biopsy Software and Data Services Market, by Country/Region, 2024-2036 (USD Million)
  • Table 10. Analyte Classes Used in Liquid Biopsy Testing
  • Table 11. Global Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 12. Global Circulating Tumor Dna Market, by Country/Region, 2024-2036 (USD Million)
  • Table 13. Global Other Cell-Free Dna Approaches Market, by Country/Region, 2024-2036 (USD Million)
  • Table 14. Global Circulating Tumor Cells Market, by Country/Region, 2024-2036 (USD Million)
  • Table 15. Global Extracellular Vesicles Market, by Country/Region, 2024-2036 (USD Million)
  • Table 16. Global Other Analytes Market, by Country/Region, 2024-2036 (USD Million)
  • Table 17. Global Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 18. Global Liquid Biopsy Market for Blood Samples, by Country/Region, 2024-2036 (USD Million)
  • Table 19. Global Liquid Biopsy Market for Urine Samples, by Country/Region, 2024-2036 (USD Million)
  • Table 20. Global Liquid Biopsy Market for Cerebrospinal Fluid Samples, by Country/Region, 2024-2036 (USD Million)
  • Table 21. Global Liquid Biopsy Market for Saliva Samples, by Country/Region, 2024-2036 (USD Million)
  • Table 22. Global Liquid Biopsy Market for Other Sample Types, by Country/Region, 2024-2036 (USD Million)
  • Table 23. Characteristics of Liquid Biopsy Testing, by Clinical Application
  • Table 24. Global Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 25. Global Liquid Biopsy Market for Therapy Selection and Companion Diagnostics, by Country/Region, 2024-2036 (USD Million)
  • Table 26. Global Liquid Biopsy Market for Treatment Monitoring, MRD and Recurrence, by Country/Region, 2024-2036 (USD Million)
  • Table 27. Global Liquid Biopsy Market for Cancer Screening and Early Detection, by Country/Region, 2024-2036 (USD Million)
  • Table 28. Global Liquid Biopsy Market for Pharmaceutical Research and Clinical Trial Services, by Country/Region, 2024-2036 (USD Million)
  • Table 29. Global Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 30. Global Liquid Biopsy Market for Lung Cancer, by Country/Region, 2024-2036 (USD Million)
  • Table 31. Global Liquid Biopsy Market for Breast Cancer, by Country/Region, 2024-2036 (USD Million)
  • Table 32. Global Liquid Biopsy Market for Colorectal Cancer, by Country/Region, 2024-2036 (USD Million)
  • Table 33. Global Liquid Biopsy Market for Prostate Cancer, by Country/Region, 2024-2036 (USD Million)
  • Table 34. Global Liquid Biopsy Market for Liver Cancer, by Country/Region, 2024-2036 (USD Million)
  • Table 35. Global Liquid Biopsy Market for Pancreatic Cancer, by Country/Region, 2024-2036 (USD Million)
  • Table 36. Global Liquid Biopsy Market for Other Cancer Types, by Country/Region, 2024-2036 (USD Million)
  • Table 37. Global Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 38. Global Liquid Biopsy Market for Diagnostic and Reference Laboratories, by Country/Region, 2024-2036 (USD Million)
  • Table 39. Global Liquid Biopsy Market for Hospitals and Clinics, by Country/Region, 2024-2036 (USD Million)
  • Table 40. Global Liquid Biopsy Market for Pharmaceutical and Biotechnology Companies, by Country/Region, 2024-2036 (USD Million)
  • Table 41. Global Liquid Biopsy Market for Academic and Research Institutes, by Country/Region, 2024-2036 (USD Million)
  • Table 42. Global Liquid Biopsy Market, by Region, 2024-2036 (USD Million)
  • Table 43. Global Liquid Biopsy Market, by Country/Region, 2024-2036 (USD Million)
  • Table 44. Global Liquid Biopsy Market, by Country/Region, 2024-2036 (Thousand Tests)
  • Table 45. North America: Liquid Biopsy Market, by Country/Region, 2024-2036 (USD Million)
  • Table 46. North America: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 47. North America: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 48. North America: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 49. North America: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 50. North America: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 51. North America: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 52. U.S.: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 53. U.S.: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 54. U.S.: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 55. U.S.: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 56. U.S.: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 57. U.S.: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 58. Canada: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 59. Canada: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 60. Canada: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 61. Canada: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 62. Canada: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 63. Canada: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 64. Europe: Liquid Biopsy Market, by Country/Region, 2024-2036 (USD Million)
  • Table 65. Europe: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 66. Europe: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 67. Europe: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 68. Europe: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 69. Europe: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 70. Europe: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 71. Germany: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 72. Germany: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 73. Germany: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 74. Germany: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 75. Germany: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 76. Germany: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 77. U.K.: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 78. U.K.: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 79. U.K.: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 80. U.K.: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 81. U.K.: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 82. U.K.: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 83. France: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 84. France: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 85. France: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 86. France: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 87. France: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 88. France: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 89. Italy: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 90. Italy: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 91. Italy: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 92. Italy: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 93. Italy: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 94. Italy: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 95. Spain: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 96. Spain: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 97. Spain: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 98. Spain: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 99. Spain: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 100. Spain: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 101. Netherlands: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 102. Netherlands: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 103. Netherlands: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 104. Netherlands: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 105. Netherlands: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 106. Netherlands: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 107. Sweden: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 108. Sweden: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 109. Sweden: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 110. Sweden: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 111. Sweden: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 112. Sweden: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 113. Switzerland: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 114. Switzerland: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 115. Switzerland: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 116. Switzerland: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 117. Switzerland: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 118. Switzerland: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 119. Rest of Europe: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 120. Rest of Europe: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 121. Rest of Europe: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 122. Rest of Europe: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 123. Rest of Europe: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 124. Rest of Europe: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 125. Asia-Pacific: Liquid Biopsy Market, by Country/Region, 2024-2036 (USD Million)
  • Table 126. Asia-Pacific: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 127. Asia-Pacific: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 128. Asia-Pacific: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 129. Asia-Pacific: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 130. Asia-Pacific: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 131. Asia-Pacific: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 132. China: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 133. China: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 134. China: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 135. China: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 136. China: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 137. China: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 138. Japan: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 139. Japan: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 140. Japan: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 141. Japan: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 142. Japan: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 143. Japan: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 144. India: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 145. India: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 146. India: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 147. India: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 148. India: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 149. India: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 150. South Korea: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 151. South Korea: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 152. South Korea: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 153. South Korea: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 154. South Korea: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 155. South Korea: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 156. Australia: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 157. Australia: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 158. Australia: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 159. Australia: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 160. Australia: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 161. Australia: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 162. Singapore: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 163. Singapore: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 164. Singapore: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 165. Singapore: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 166. Singapore: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 167. Singapore: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 168. Rest of Asia-Pacific: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 169. Rest of Asia-Pacific: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 170. Rest of Asia-Pacific: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 171. Rest of Asia-Pacific: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 172. Rest of Asia-Pacific: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 173. Rest of Asia-Pacific: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 174. Latin America: Liquid Biopsy Market, by Country/Region, 2024-2036 (USD Million)
  • Table 175. Latin America: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 176. Latin America: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 177. Latin America: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 178. Latin America: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 179. Latin America: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 180. Latin America: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 181. Brazil: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 182. Brazil: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 183. Brazil: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 184. Brazil: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 185. Brazil: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 186. Brazil: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 187. Mexico: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 188. Mexico: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 189. Mexico: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 190. Mexico: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 191. Mexico: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 192. Mexico: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 193. Rest of Latin America: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 194. Rest of Latin America: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 195. Rest of Latin America: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 196. Rest of Latin America: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 197. Rest of Latin America: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 198. Rest of Latin America: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 199. Middle East & Africa: Liquid Biopsy Market, by Country/Region, 2024-2036 (USD Million)
  • Table 200. Middle East & Africa: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 201. Middle East & Africa: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 202. Middle East & Africa: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 203. Middle East & Africa: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 204. Middle East & Africa: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 205. Middle East & Africa: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 206. U.A.E.: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 207. U.A.E.: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 208. U.A.E.: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 209. U.A.E.: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 210. U.A.E.: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 211. U.A.E.: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 212. Saudi Arabia: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 213. Saudi Arabia: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 214. Saudi Arabia: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 215. Saudi Arabia: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 216. Saudi Arabia: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 217. Saudi Arabia: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 218. South Africa: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 219. South Africa: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 220. South Africa: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 221. South Africa: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 222. South Africa: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 223. South Africa: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 224. Rest of Middle East & Africa: Liquid Biopsy Market, by Products and Services, 2024-2036 (USD Million)
  • Table 225. Rest of Middle East & Africa: Liquid Biopsy Market, by Biomarker/Analyte, 2024-2036 (USD Million)
  • Table 226. Rest of Middle East & Africa: Liquid Biopsy Market, by Sample Type, 2024-2036 (USD Million)
  • Table 227. Rest of Middle East & Africa: Liquid Biopsy Market, by Application, 2024-2036 (USD Million)
  • Table 228. Rest of Middle East & Africa: Liquid Biopsy Market, by Cancer Type, 2024-2036 (USD Million)
  • Table 229. Rest of Middle East & Africa: Liquid Biopsy Market, by End User, 2024-2036 (USD Million)
  • Table 230. Competitive Benchmarking of Leading Liquid Biopsy Providers
  • Table 231. Guardant Health, Inc.: Liquid Biopsy Product Portfolio
  • Table 232. Guardant Health, Inc.: Strategic Developments (2024-2026)
  • Table 233. Roche Diagnostics: Liquid Biopsy Product Portfolio
  • Table 234. Roche Diagnostics: Strategic Developments (2024-2026)
  • Table 235. Natera, Inc.: Liquid Biopsy Product Portfolio
  • Table 236. Natera, Inc.: Strategic Developments (2024-2026)
  • Table 237. Abbott Laboratories (Exact Sciences): Liquid Biopsy Product Portfolio
  • Table 238. Abbott Laboratories (Exact Sciences): Strategic Developments (2024-2026)
  • Table 239. Tempus AI, Inc.: Liquid Biopsy Product Portfolio
  • Table 240. Tempus AI, Inc.: Strategic Developments (2024-2026)
  • Table 241. Caris Life Sciences, Inc.: Liquid Biopsy Product Portfolio
  • Table 242. Caris Life Sciences, Inc.: Strategic Developments (2024-2026)
  • Table 243. Personalis, Inc.: Liquid Biopsy Product Portfolio
  • Table 244. Personalis, Inc.: Strategic Developments (2024-2026)
  • Table 245. Illumina, Inc.: Liquid Biopsy Product Portfolio
  • Table 246. Illumina, Inc.: Strategic Developments (2024-2026)
  • Table 247. Thermo Fisher Scientific Inc.: Liquid Biopsy Product Portfolio
  • Table 248. Thermo Fisher Scientific Inc.: Strategic Developments (2024-2026)
  • Table 249. QIAGEN N.V.: Liquid Biopsy Product Portfolio
  • Table 250. QIAGEN N.V.: Strategic Developments (2024-2026)
  • Table 251. Bio-Rad Laboratories, Inc.: Liquid Biopsy Product Portfolio
  • Table 252. Bio-Rad Laboratories, Inc.: Strategic Developments (2024-2026)
  • Table 253. NeoGenomics, Inc.: Liquid Biopsy Product Portfolio
  • Table 254. NeoGenomics, Inc.: Strategic Developments (2024-2026)
  • Table 255. Myriad Genetics, Inc.: Liquid Biopsy Product Portfolio
  • Table 256. Myriad Genetics, Inc.: Strategic Developments (2024-2026)
  • Table 257. Sysmex Corporation: Liquid Biopsy Product Portfolio
  • Table 258. Sysmex Corporation: Strategic Developments (2024-2026)
  • Table 259. Menarini Silicon Biosystems: Liquid Biopsy Product Portfolio
  • Table 260. Menarini Silicon Biosystems: Strategic Developments (2024-2026)
  • Table 261. BillionToOne, Inc.: Liquid Biopsy Product Portfolio
  • Table 262. BillionToOne, Inc.: Strategic Developments (2024-2026)
  • Table 263. Burning Rock Biotech Limited: Liquid Biopsy Product Portfolio
  • Table 264. Burning Rock Biotech Limited: Strategic Developments (2024-2026)
  • Table 265. Amoy Diagnostics Co., Ltd.: Liquid Biopsy Product Portfolio
  • Table 266. Amoy Diagnostics Co., Ltd.: Strategic Developments (2024-2026)

LIST OF FIGURES

List of Figures

  • Figure 1. Liquid Biopsy Market: Scope and Segmentation
  • Figure 2. Market Boundary: What Is Counted as Liquid Biopsy Revenue
  • Figure 3. Liquid Biopsy Market Ecosystem
  • Figure 4. Currency Conversion Rates Used in the Study (Annual Average Rates, 2024-2025)
  • Figure 5. Key Stakeholders in the Liquid Biopsy Market
  • Figure 6. Research Process
  • Figure 7. Secondary Sources Referenced for This Study
  • Figure 8. Primary Research Techniques
  • Figure 9. Key Executives Interviewed
  • Figure 10. Breakdown of Primary Interviews (Supply Side & Demand Side)
  • Figure 11. Market Sizing and Growth Forecast Approach
  • Figure 12. Data Triangulation
  • Figure 13. Global Liquid Biopsy Market Value and Test Volume, 2026-2036
  • Figure 14. Global Liquid Biopsy Market, by Products and Services, 2026 vs. 2036 (USD Million)
  • Figure 15. Global Liquid Biopsy Market, by Biomarker/Analyte, 2026 vs. 2036 (USD Million)
  • Figure 16. Global Liquid Biopsy Market, by Sample Type, 2026 vs. 2036 (USD Million)
  • Figure 17. Global Liquid Biopsy Market, by Application, 2026 vs. 2036 (USD Million)
  • Figure 18. Global Liquid Biopsy Market, by Cancer Type, 2026 vs. 2036 (USD Million)
  • Figure 19. Global Liquid Biopsy Market, by End User, 2026 vs. 2036 (USD Million)
  • Figure 20. Global Liquid Biopsy Market, by Region, 2026 vs. 2036 (USD Million)
  • Figure 21. Factors Analysis: Impact on Market Growth
  • Figure 22. Key Milestones Shaping the Liquid Biopsy Market
  • Figure 23. Value Chain Analysis of the Liquid Biopsy Market
  • Figure 24. Regulatory Framework for Liquid Biopsy Testing, by Region
  • Figure 25. Published Prices and Reimbursement Rates for Selected Liquid Biopsy Tests
  • Figure 26. Porter's Five Forces Analysis of the Liquid Biopsy Market
  • Figure 27. PESTEL Analysis of the Liquid Biopsy Market
  • Figure 28. Global Liquid Biopsy Market, by Products and Services, 2026 vs. 2036 (USD Million)
  • Figure 29. Global Liquid Biopsy Market, by Biomarker/Analyte, 2026 vs. 2036 (USD Million)
  • Figure 30. Global Liquid Biopsy Market, by Sample Type, 2026 vs. 2036 (USD Million)
  • Figure 31. Global Liquid Biopsy Market, by Application, 2026 vs. 2036 (USD Million)
  • Figure 32. Global Liquid Biopsy Market, by Cancer Type, 2026 vs. 2036 (USD Million)
  • Figure 33. Global Liquid Biopsy Market, by End User, 2026 vs. 2036 (USD Million)
  • Figure 34. Global Liquid Biopsy Market, by Region, 2026 vs. 2036 (USD Million)
  • Figure 35. North America: Liquid Biopsy Market Snapshot
  • Figure 36. Europe: Liquid Biopsy Market Snapshot
  • Figure 37. Asia-Pacific: Liquid Biopsy Market Snapshot
  • Figure 38. Latin America: Liquid Biopsy Market Snapshot
  • Figure 39. Middle East & Africa: Liquid Biopsy Market Snapshot
  • Figure 40. Key Growth Strategies Adopted by Leading Players (2024-2026)
  • Figure 41. Competitive Dashboard: Liquid Biopsy Market
  • Figure 42. Market Share Analysis, by Key Player (2025)
  • Figure 43. Guardant Health, Inc.: Financial Snapshot
  • Figure 44. Guardant Health, Inc.: SWOT Analysis
  • Figure 45. Roche Diagnostics Division: Financial Snapshot
  • Figure 46. Roche Diagnostics: SWOT Analysis
  • Figure 47. Natera, Inc.: Financial Snapshot
  • Figure 48. Natera, Inc.: SWOT Analysis
  • Figure 49. Exact Sciences: Financial Snapshot
  • Figure 50. Abbott Laboratories (Exact Sciences): SWOT Analysis
  • Figure 51. Tempus AI, Inc.: Financial Snapshot
  • Figure 52. Tempus AI, Inc.: SWOT Analysis
  • Figure 53. Caris Life Sciences, Inc.: Financial Snapshot
  • Figure 54. Caris Life Sciences, Inc.: SWOT Analysis
  • Figure 55. Personalis, Inc.: Financial Snapshot
  • Figure 56. Personalis, Inc.: SWOT Analysis
  • Figure 57. Illumina, Inc.: Financial Snapshot
  • Figure 58. Illumina, Inc.: SWOT Analysis
  • Figure 59. Thermo Fisher Scientific Inc.: Financial Snapshot
  • Figure 60. Thermo Fisher Scientific Inc.: SWOT Analysis
  • Figure 61. QIAGEN N.V.: Financial Snapshot
  • Figure 62. QIAGEN N.V.: SWOT Analysis
  • Figure 63. Bio-Rad Laboratories, Inc.: Financial Snapshot
  • Figure 64. Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 65. NeoGenomics, Inc.: Financial Snapshot
  • Figure 66. NeoGenomics, Inc.: SWOT Analysis
  • Figure 67. Myriad Genetics, Inc.: Financial Snapshot
  • Figure 68. Myriad Genetics, Inc.: SWOT Analysis
  • Figure 69. Sysmex Corporation: Key Facts
  • Figure 70. Sysmex Corporation: SWOT Analysis
  • Figure 71. Menarini Silicon Biosystems: Key Facts
  • Figure 72. Menarini Silicon Biosystems: SWOT Analysis
  • Figure 73. BillionToOne, Inc.: Key Facts
  • Figure 74. BillionToOne, Inc.: SWOT Analysis
  • Figure 75. Burning Rock Biotech Limited: Key Facts
  • Figure 76. Burning Rock Biotech Limited: SWOT Analysis
  • Figure 77. Amoy Diagnostics Co., Ltd.: Key Facts
  • Figure 78. Amoy Diagnostics Co., Ltd.: SWOT Analysis
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!